Karo Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (€319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (€141m).
Deep Branch Biotechnology Ltd. from Nottingham has started a feasibility study with the British energy supplier Drax Group. The technology to be analysed converts carbon dioxide emitted by power stations into protein that could be used for feeding fish and livestock.
German GM proponents have taken action against discrimination of food products generated by gene editing.
Roche and US company Hesperos Inc have used human cancer and organ cells, placed in a 5-chamber microfluidic chip, to predict chemotherapy safety and efficacy preclinically.
Valo Therapeutics Limited, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines has appointed Michael Stein to Chief Executive Officer. Stein already served as part-time co-Chairman since the company’s inception in 2017.
As food producers are taking up current health and sustainability trends more and more, the next EFIB (30 September??2 October, 2019) will see a lot of technology providers and ingredient producers showcasing biotechnological solutions in Brussels. European Biotechnology spoke with Dr Gerhard Schmid, Head, Wacker Biosolutions, about the market, challenges, and growth strategies within the bioeconomy.
Researchers from Israel and the UK have identified how the cytokine IL-23 triggers inflammatory bowel syndrome (IBD), which affects 1.6 million patients annually in the US alone.
![A laser-based technique detects circulating tumour cells in the veins of patients with melanoma.
[Credit: E.I. Galanzha et al., Science Translational Medicine (2019)]](https://european-biotechnology.com/wp-content/uploads/2024/04/CTCs_galanzha1HR-180x180.jpg "CTCs_galanzha1HR.jpg")
German and US researchers have developed a diagnostic technique capable to detect one single circulating tumour cell in one litre of blood.
Nobel Laureate Dr James Allison and Oncologist Dr Padmanee Sharma from the MD Anderson Cancer Center to join the company as Company Strategic Advisors
ReViral Ltd., a clinical-stage company focused on developing novel, antiviral compounds that target respiratory syncytial virus (RSV), today announced that Alex C. Sapir has been appointed Chief Executive Officer (CEO) and elected to the Board of Directors, effective June 10, 2019. Mr. Sapir succeeds Dr. Eddy Littler, who will serve as Chief Operating Officer (COO).